Kevin P. Hill, MD, MHS, is an addiction psychiatrist, Director of the Division of Addiction Psychiatry at Beth Israel Deaconess Medical Center and an Assistant Professor of Psychiatry at Harvard Medical School.
Dr. Hill grew up in Rochester, New York and attended McQuaid Jesuit High School. He subsequently graduated from Skidmore College and Jefferson Medical College before training in psychiatry at the Harvard Longwood Psychiatry Residency Training Program. He earned a Masters in Health Sciences from the Robert Wood Johnson Clinical Scholars Program at Yale and also completed the Partners Healthcare Addiction Psychiatry Fellowship Program.
Dr. Hill’s clinical research is focused primarily on medications and behavioral interventions that might improve available treatments for those wanting to stop smoking marijuana. Dr. Hill was the recipient of a prestigious federal K99/R00 grant award from the National Institute on Drug Abuse (NIDA) to test the efficacy of a synthetic marijuana-like compound, nabilone, as a potential medication treatment for patients with marijuana addiction. His work has been funded by NIDA, the Brain and Behavior Research Foundations, the American Lung Association, the Greater Boston Council on Alcoholism, and the Peter G. Dodge Foundation. He has received multiple competitive awards as an investigator and published on numerous topics in addiction.
In addition to the clinical trials he directs, Dr. Hill sees patients in his private practice and consults to the Boston Red Sox, the National Football League, and the National Basketball Association.
- American Board of Psychiatry & Neurology (Addiction Psychiatry)
- American Board of Psychiatry & Neurology (Psychiatry)
- Hill, K. P., & Saxon, A. J. (2018). The Role of Cannabis Legalization in the Opioid Crisis. JAMA internal medicine, 178(5), 679-680.